Please use this identifier to cite or link to this item: http://hdl.handle.net/123456789/29818
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChean-Ring Leong-
dc.contributor.authorWoei-Yenn Tong-
dc.contributor.author(UNIKL MICET)-
dc.date.accessioned2024-04-17T02:42:53Z-
dc.date.available2024-04-17T02:42:53Z-
dc.date.issued2024-04-17-
dc.identifier.urihttp://hdl.handle.net/123456789/29818-
dc.descriptionThis article is index by Scopusen_US
dc.description.abstractMethicillin-resistant Staphylococcus aureus (MRSA) infections have become one of the most threatening multidrug-resistant pathogens. Thus, an ongoing search for anti-MRSA compounds remains an urgent need to effectively treating MRSA infections. Phomopsidione, a novel antibiotic isolated from Diaporthe fraxini, has previously demonstrated potent anti-candidal activity. The present study aimed to investigate the effects of phomopsidione on the viability, virulence, and metabolites profile of MRSA. MRSA was sensitive to phomopsidione in a concentration-dependent manner. Phomopsidione exhibited minimum inhibitory concentration and minimum bactericidal concentration of 62.5 and 500.00 µg/mL against MRSA on broth microdilution assay. The compound showed significant reduction in virulence factors production including extracellular polymeric substances quantification, catalase, and lipase. An untargeted metabolomics analysis using liquid chromatography-high resolution mass spectrometry revealed a significant difference in the metabolites profile of MRSA with 13 putatively identified discriminant metabolites. The present study suggested the potential of phomopsidione as a promising anti-MRSA agent.en_US
dc.titleEffects of Phomopsidione on the Viability, Virulence, and Metabolites Profile of Methicillin-Resistant Staphylococcus aureus (MRSA)en_US
dc.typeArticleen_US
Appears in Collections:Journal Articles

Files in This Item:
File Description SizeFormat 
Scopus March 2024_Part5.pdf140.84 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.